Cantor Fitzgerald L. P. Takes $82,000 Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

Cantor Fitzgerald L. P. purchased a new position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 20,000 shares of the company’s stock, valued at approximately $82,000.

Other large investors also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. boosted its holdings in shares of Trevi Therapeutics by 220.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 100,517 shares of the company’s stock worth $336,000 after purchasing an additional 69,167 shares during the period. Geode Capital Management LLC boosted its position in shares of Trevi Therapeutics by 10.2% during the third quarter. Geode Capital Management LLC now owns 1,264,166 shares of the company’s stock valued at $4,223,000 after buying an additional 117,418 shares during the period. Charles Schwab Investment Management Inc. grew its stake in shares of Trevi Therapeutics by 14.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 173,063 shares of the company’s stock valued at $713,000 after buying an additional 22,145 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of Trevi Therapeutics by 42.0% in the fourth quarter. Renaissance Technologies LLC now owns 100,400 shares of the company’s stock worth $414,000 after buying an additional 29,700 shares during the period. Finally, American Century Companies Inc. boosted its holdings in Trevi Therapeutics by 44.7% during the 4th quarter. American Century Companies Inc. now owns 78,143 shares of the company’s stock valued at $322,000 after acquiring an additional 24,153 shares during the period. 95.76% of the stock is owned by institutional investors.

Trevi Therapeutics Trading Down 1.3 %

Shares of NASDAQ TRVI opened at $6.90 on Tuesday. The stock has a market capitalization of $689.26 million, a PE ratio of -15.68 and a beta of 0.62. Trevi Therapeutics, Inc. has a 12-month low of $2.30 and a 12-month high of $7.39. The stock’s fifty day simple moving average is $5.98 and its two-hundred day simple moving average is $4.44.

Trevi Therapeutics (NASDAQ:TRVI) last posted its earnings results on Tuesday, March 18th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.01. On average, equities analysts predict that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current fiscal year.

Insider Activity at Trevi Therapeutics

In related news, CEO Jennifer L. Good sold 5,263 shares of the company’s stock in a transaction dated Friday, March 21st. The stock was sold at an average price of $6.58, for a total transaction of $34,630.54. Following the transaction, the chief executive officer now directly owns 213,313 shares of the company’s stock, valued at $1,403,599.54. This represents a 2.41 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Farrell Simon sold 81,313 shares of the firm’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $6.75, for a total value of $548,862.75. Following the completion of the sale, the insider now directly owns 76,900 shares of the company’s stock, valued at approximately $519,075. This represents a 51.39 % decrease in their position. The disclosure for this sale can be found here. 24.37% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research firms have recently weighed in on TRVI. HC Wainwright reiterated a “buy” rating and set a $12.50 target price on shares of Trevi Therapeutics in a research report on Wednesday, March 19th. Raymond James raised shares of Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and boosted their price objective for the company from $9.00 to $29.00 in a research report on Monday, March 10th. B. Riley reaffirmed a “buy” rating and set a $20.00 price target (up previously from $11.00) on shares of Trevi Therapeutics in a research note on Wednesday, March 19th. Needham & Company LLC reissued a “buy” rating and issued a $24.00 price objective on shares of Trevi Therapeutics in a research note on Tuesday, April 8th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $21.00 target price on shares of Trevi Therapeutics in a research report on Wednesday, March 19th. Seven research analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $17.56.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.